Sean Bedingfield

Sean Bedingfield

Company: Eli Lilly Company – New Therapeutic Modalities

Job title: Research Engineer – Drug Delivery

Seminars:

Moderated Discussion – Consideration of Gene Therapy Effectiveness Resulting from Insights into Genetic Predisposition 5:45 pm

Read more

day: Day One

Considerations in Utilizing Oligonucleotide-Based Therapeutics to Prevent or Treat HFpEF 4:45 pm

What are the circumstances and performance criteria to justify oligonucleotide use when small molecule inhibitors are clinically available? Assess antisense oligonucleotides, small interfering RNA, and prevalent delivery strategies with their respective strengths and weaknesses Hear best case practices in experimental evaluation of renal and endocrine oligonucleotide therapiesRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.